CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 24 target
Drug / intervention
G207biological
Likely dose
Not stated in record
Key inclusion· 8
  • ✓Age ≥36 months and <22 years
  • ✓Pathologically proven malignant cerebellar brain tumor (medulloblastoma, glioblastoma, astrocytoma, PNET, ependymoma, atypical teratoid/rhabdoid, germ cell, or other high-grade malignant tumor)
  • ✓Progressive or recurrent despite standard care
  • ✓Tumor ≥1.0 cm to ≤3.0 cm in diameter and surgically accessible
Key exclusion· 11
  • ✕Diffuse, widespread abnormal tumor pattern involving 3 or more brain lobes
  • ✕Acute infection, granulocytopenia, or medical condition precluding surgery
  • ✕Pregnant or lactating females
  • ✕Encephalitis or CNS infection <3 months prior, or ongoing treatment for encephalitis, CNS infection, or multiple sclerosis

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03911388
NCT03911388Phase 1RecruitingOn Track
Long Recruiting
CompareCT.gov

Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

M.D. Anderson Cancer Center·interventional·Posted Apr 11, 2019·Updated May 15, 2026

In Brief

A Phase 1 clinical trial evaluating G207 for Neoplasms, Brain and 32 related conditions. Currently recruiting, targeting 24 participants across 3 sites.

Detailed Summary

This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Funding Source- FDA OOPD

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum, Neoplasms, Astrocytoma, Astrocytoma, Cerebellar, Neuroectodermal Tumors, Neuroectodermal Tumors, Primitive, Cerebellar PNET, Childhood, Cerebellar Neoplasms, Cerebellar Neoplasms, Primary, Cerebellar Neoplasm, Malignant, Cerebellar Neoplasm Malignant Primary, Neoplasm Metastases, Neoplasm Malignant, Neoplasms, Neuroepithelial, Neoplasms, Germ Cell and Embryonal, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Central Nervous System Neoplasms, Primary, Central Nervous System Neoplasms, Malignant, Nervous System Neoplasms, Neoplasms by Site, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Medulloblastoma Recurrent, HSV, Virus, Pediatric Brain Tumor, Nervous System Cancer, Primitive Neuroectodermal Tumor (PNET) of Cerebellum
CountriesUnited States
CollaboratorsCannonball Kids' Cancer Foundation, Treovir, Inc

Timeline

Phase 1Recruiting
20202021202220232024202520262027
First PostedApr 11, 2019
Enrollment StartSep 12, 2019
Primary CompletionSep 1, 2026
Study CompletionSep 1, 2027
TodayJul 2, 2026
Enrollment to primary: 7.0 yearsPosted 7.2 years agoPrimary completion in 2 months

Interventions

G207biological

Single dose of G207 infused through catheters into region(s) of tumor. If G207 is safe in the first cohort of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor followed by a 5 Gy dose of radiation to the tumor (which includes progressive leptomeningeal disease or any site of gross tumor progressing in the brain parenchyma) within 24 hours of virus inoculation.